Intercept to Present at Leerink Global Healthcare Conference
NEW YORK, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver and intestinal diseases, today announced that Mark
Pruzanski, M.D., President and Chief Executive Officer, will present at the
Leerink Global Healthcare Conference in New York on Thursday, February 13,
2014 at 2:15 p.m. Eastern Time
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver and intestinal diseases utilizing its expertise in bile acid chemistry.
The company's lead product candidate, obeticholic acid (OCA), is a bile acid
analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is
being developed for a variety of chronic liver diseases including primary
biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal
hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA
has received orphan drug designation in both the United States and Europe for
the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside
of Japan and China, where it has out-licensed the product candidate to
Dainippon Sumitomo Pharma. For more information about Intercept, please visit
the Company's website at: www.interceptpharma.com.
CONTACT: Barbara Duncan or Senthil Sundaram
Media inquiries: firstname.lastname@example.org
Investor inquiries: email@example.com
Press spacebar to pause and continue. Press esc to stop.